AZTA Quote, Financials, Valuation and Earnings

Bruker Corp. has a net margin of 31.94% compared to Azenta, Inc.'s net margin of -6.8%. Azenta, Inc.'s return on equity of 1.39% beat Bruker Corp.'s return on equity of -1.2%.

Azenta, Inc. has a consensus price target of $39.83, signalling upside risk potential of 13.49%. On the other hand Bruker Corp. has an analysts' consensus of $48.83 which suggests that it could grow by 0.94%. Given that Azenta, Inc. has higher upside potential than Bruker Corp., analysts believe Azenta, Inc. is more attractive than Bruker Corp..

Azenta, Inc. has a beta of 1.288, which suggesting that the stock is 28.831% more volatile than S&P 500. In comparison Bruker Corp. has a beta of 1.174, suggesting its more volatile than the S&P 500 by 17.405%.

Azenta, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bruker Corp. offers a yield of 0.41% to investors and pays a quarterly dividend of $0.05 per share. Azenta, Inc. pays -- of its earnings as a dividend. Bruker Corp. pays out 26.44% of its earnings as a dividend. Bruker Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Azenta, Inc. quarterly revenues are $159.2M, which are smaller than Bruker Corp. quarterly revenues of $860.5M. Azenta, Inc.'s net income of $50.9M is higher than Bruker Corp.'s net income of -$58.5M. Notably, Azenta, Inc.'s price-to-earnings ratio is -- while Bruker Corp.'s PE ratio is 77.08x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Azenta, Inc. is 2.71x versus 2.14x for Bruker Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Harvard Bioscience, Inc. has a net margin of 31.94% compared to Azenta, Inc.'s net margin of -5.98%. Azenta, Inc.'s return on equity of 1.39% beat Harvard Bioscience, Inc.'s return on equity of -155.33%.

Azenta, Inc. has a consensus price target of $39.83, signalling upside risk potential of 13.49%. On the other hand Harvard Bioscience, Inc. has an analysts' consensus of $2.00 which suggests that it could grow by 174.88%. Given that Harvard Bioscience, Inc. has higher upside potential than Azenta, Inc., analysts believe Harvard Bioscience, Inc. is more attractive than Azenta, Inc..

Azenta, Inc. has a beta of 1.288, which suggesting that the stock is 28.831% more volatile than S&P 500. In comparison Harvard Bioscience, Inc. has a beta of 1.531, suggesting its more volatile than the S&P 500 by 53.123%.

Azenta, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Harvard Bioscience, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Azenta, Inc. pays -- of its earnings as a dividend. Harvard Bioscience, Inc. pays out -- of its earnings as a dividend.

Azenta, Inc. quarterly revenues are $159.2M, which are larger than Harvard Bioscience, Inc. quarterly revenues of $20.6M. Azenta, Inc.'s net income of $50.9M is higher than Harvard Bioscience, Inc.'s net income of -$1.2M. Notably, Azenta, Inc.'s price-to-earnings ratio is -- while Harvard Bioscience, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Azenta, Inc. is 2.71x versus 0.37x for Harvard Bioscience, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Kestra Medical Technologies Ltd. has a net margin of 31.94% compared to Azenta, Inc.'s net margin of -133.32%. Azenta, Inc.'s return on equity of 1.39% beat Kestra Medical Technologies Ltd.'s return on equity of -104.63%.

Azenta, Inc. has a consensus price target of $39.83, signalling upside risk potential of 13.49%. On the other hand Kestra Medical Technologies Ltd. has an analysts' consensus of $27.86 which suggests that it could grow by 7.89%. Given that Azenta, Inc. has higher upside potential than Kestra Medical Technologies Ltd., analysts believe Azenta, Inc. is more attractive than Kestra Medical Technologies Ltd..

Azenta, Inc. has a beta of 1.288, which suggesting that the stock is 28.831% more volatile than S&P 500. In comparison Kestra Medical Technologies Ltd. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Azenta, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Kestra Medical Technologies Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Azenta, Inc. pays -- of its earnings as a dividend. Kestra Medical Technologies Ltd. pays out 1.45% of its earnings as a dividend. Kestra Medical Technologies Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Azenta, Inc. quarterly revenues are $159.2M, which are larger than Kestra Medical Technologies Ltd. quarterly revenues of $19.4M. Azenta, Inc.'s net income of $50.9M is higher than Kestra Medical Technologies Ltd.'s net income of -$25.8M. Notably, Azenta, Inc.'s price-to-earnings ratio is -- while Kestra Medical Technologies Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Azenta, Inc. is 2.71x versus 14.98x for Kestra Medical Technologies Ltd.. Usually stocks with elevated PS ratios are considered overvalued.

Phibro Animal Health Corp. has a net margin of 31.94% compared to Azenta, Inc.'s net margin of 7.29%. Azenta, Inc.'s return on equity of 1.39% beat Phibro Animal Health Corp.'s return on equity of 24.77%.

Azenta, Inc. has a consensus price target of $39.83, signalling upside risk potential of 13.49%. On the other hand Phibro Animal Health Corp. has an analysts' consensus of $43.00 which suggests that it could grow by 3.89%. Given that Azenta, Inc. has higher upside potential than Phibro Animal Health Corp., analysts believe Azenta, Inc. is more attractive than Phibro Animal Health Corp..

Azenta, Inc. has a beta of 1.288, which suggesting that the stock is 28.831% more volatile than S&P 500. In comparison Phibro Animal Health Corp. has a beta of 0.771, suggesting its less volatile than the S&P 500 by 22.868%.

Azenta, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Phibro Animal Health Corp. offers a yield of 1.16% to investors and pays a quarterly dividend of $0.12 per share. Azenta, Inc. pays -- of its earnings as a dividend. Phibro Animal Health Corp. pays out 40.46% of its earnings as a dividend. Phibro Animal Health Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Azenta, Inc. quarterly revenues are $159.2M, which are smaller than Phibro Animal Health Corp. quarterly revenues of $363.9M. Azenta, Inc.'s net income of $50.9M is higher than Phibro Animal Health Corp.'s net income of $26.5M. Notably, Azenta, Inc.'s price-to-earnings ratio is -- while Phibro Animal Health Corp.'s PE ratio is 24.88x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Azenta, Inc. is 2.71x versus 1.21x for Phibro Animal Health Corp.. Usually stocks with elevated PS ratios are considered overvalued.